Get started
Palvella Therapeutics, Inc.Palvella Therapeutics, Inc.Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PVLA chart


Full chart

PVLA upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪314.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−12.61 USD
Net income (FY)
‪−24.54 M‬ USD
Revenue (FY)
‪42.81 M‬ USD
Shares float
‪6.69 M‬
Beta (1Y)
−0.55

Employees


Employees (FY)
50
Change (1Y)
−94 −65.28%
Revenue / Employee (1Y)
‪856.20 K‬ USD
Net income / Employee (1Y)
‪−490.86 K‬ USD

About Palvella Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Wesley H. Kaupinen
Website
palvellatx.com
Headquarters
Wayne
Founded
2015
FIGI
BBG0055C3N57
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It is developing a pipeline of innovative treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PVLA news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.


Frequently Asked Questions


The current price of PVLA is 29.00 USD — it has increased by 11.25% in the past 24 hours. Watch Palvella Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Palvella Therapeutics, Inc. stocks are traded under the ticker PVLA.
PVLA stock has risen by 38.43% compared to the previous week, the month change is a 79.65% rise, over the last year Palvella Therapeutics, Inc. has showed a −97.25% decrease.
We've gathered analysts' opinions on Palvella Therapeutics, Inc. future price: according to them, PVLA price has a max estimate of 50.00 USD and a min estimate of 30.00 USD. Watch PVLA chart and read a more detailed Palvella Therapeutics, Inc. stock forecast: see what analysts think of Palvella Therapeutics, Inc. and suggest that you do with its stocks.
PVLA reached its all-time high on Feb 13, 2018 with the price of 62,400.00 USD, and its all-time low was 6.20 USD and was reached on Jul 12, 2024. View more price dynamics on PVLA chart.
See other stocks reaching their highest and lowest prices.
PVLA stock is 7.12% volatile and has beta coefficient of −0.55. Track Palvella Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Palvella Therapeutics, Inc. there?
Today Palvella Therapeutics, Inc. has the market capitalization of ‪314.08 M‬, it has increased by 25.29% over the last week.
Yes, you can track Palvella Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Palvella Therapeutics, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
PVLA earnings for the last quarter are −1.18 USD per share, whereas the estimation was −4.00 USD resulting in a 70.50% surprise. The estimated earnings for the next quarter are −0.67 USD per share. See more details about Palvella Therapeutics, Inc. earnings.
Palvella Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪1.07 M‬ USD. In the next quarter, revenue is expected to reach 0.00 USD.
PVLA net income for the last quarter is ‪−2.89 M‬ USD, while the quarter before that showed ‪−3.59 M‬ USD of net income which accounts for 19.58% change. Track more Palvella Therapeutics, Inc. financial stats to get the full picture.
No, PVLA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 13, 2025, the company has 50.00 employees. See our rating of the largest employees — is Palvella Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Palvella Therapeutics, Inc. EBITDA is ‪−18.35 M‬ USD, and current EBITDA margin is −32.85%. See more stats in Palvella Therapeutics, Inc. financial statements.
Like other stocks, PVLA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Palvella Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Palvella Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Palvella Therapeutics, Inc. stock shows the neutral signal. See more of Palvella Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.